[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506975":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":34,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Power Life Sciences Inc.","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Michael B Gill","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","415-900-4227","bask@withpower.com",[18],{"facility":19,"status":7,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Power Life Sciences","San Francisco","California","94107","United States","US",{"type":26,"coordinates":27},"Point",[28,29],-122.41942,37.77493,{"lat":29,"lon":28},[32],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":33},"https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100506975","examining-clinical-research-participation-for-substance-abuse-disorder-patient-100506975",false,"NCT05881369","Examining Clinical Research Participation for Substance Abuse Disorder Patient","Exploring the Clinical Trial Journey of Patients in Substance Abuse Disorder Clinical Trials","Inclusion Criteria:\n\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.\n* Participant has a diagnosis of substance abuse disorder.\n* Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.\n\nExclusion Criteria:\n\n* Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.\n* Pregnant or lactating woman\n* Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results","ALL","18 Years",{"count":46,"type":47},500,"ESTIMATED","OBSERVATIONAL","Clinical study participation percentages haven't always been fully representative of a given demographic.\n\nThe goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through.\n\nThe data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future substance abuse disorder patients during clinical trials.",[51],"Substance Abuse Disorder",[53],"substance abuse disorder","NOT_YET_RECRUITING","2023-05-19",{"date":57,"type":58},"2023-05-31","ACTUAL",{"date":60,"type":47},"2024-06",{"date":62,"type":47},"2026-06",{"name":5,"class":6},1]